CRA is proud to announce the addition of Patrick Hillan as a Vice President in the firm’s Life Sciences Practice.
“I am happy to welcome Patrick to CRA,” said Paul Maleh, President and Chief Executive Officer of Charles River Associates. “He has deep expertise in medical affairs strategy, having partnered with global pharmaceutical and biotechnology companies across a broad range of therapeutic areas to generate actionable stakeholder insights, develop evidence-based strategies, and support successful product launches worldwide.”
“Patrick’s expertise in medical affairs will be instrumental as we continue to enhance and scale our life sciences advisory services,” said Dr. Gregory K. Bell, CRA Group Vice President and Life Sciences Practice Leader “His ability to translate stakeholder insights, scientific evidence, and evolving market dynamics into actionable medical strategies will strengthen the support we provide to medical affairs teams, while helping clients make informed decisions to support successful launches, and maximize the value of their innovations.
Prior to joining CRA, Mr. Hillan was a partner at a life sciences consulting firm, where he advised pharmaceutical and biotechnology companies on medical affairs strategy and launch readiness across a broad range of therapeutic areas. He led engagements spanning healthcare professional and patient insight generation, strategic and tactical planning, integrated evidence generation planning, and scientific platform and narrative development, helping organizations build the scientific and strategic foundations needed to support successful product launches and optimize asset value throughout the product lifecycle.
Mr. Hillan holds a MSc in Neuroscience and a BSc in Biological Sciences from the University of Edinburgh.
About CRA’s Life Sciences Practice
CRA’s Life Sciences Practice works with leading biotech, medical device, and pharmaceutical companies; law firms; regulatory agencies; and national and international industry associations. We provide the analytical expertise and industry experience needed to address our clients’ toughest issues. We have a reputation for rigorous and innovative analysis, careful attention to detail, and the ability to work effectively as part of a wider team of advisers.
